Significant Hemolysis Not Required for Thrombosis in PNH
By LabMedica International staff writers Posted on 19 Mar 2019 |

Image: Bone marrow aspirate of a patient with paroxysmal nocturnal hemoglobinuria showing erythroid hyperplasia with occasional nuclear budding consistent with stressed erythropoiesis (Photo courtesy of Katherine Calco).
Paroxysmal nocturnal hemoglobinuria (PNH), a rare hematological condition, presents with hemolytic or thrombotic symptoms. Cumulative thrombosis incidence in PNH over an eight to ten-year period is 23% to 30%, 20% of patients have multi-site thrombosis and 10% present with thrombosis.
PNH stem cells arise due to somatic mutations in the phosphatidylinositol glycan A (PIGA) gene in bone marrow stem cells, resulting in loss of the glycosylphosphatidylinositol anchor protein (GPI anchor). Loss of this GPI anchor results in absence of CD55 and CD59, complement regulatory proteins on hematopoietic cells, rendering red blood cells susceptible to complement attack and intravascular hemolysis.
Hematologists at St James University Hospital (Leeds, UK) and their colleagues retrospectively interrogated the Leeds (UK) PNH database. Patients with PNH granulocyte or monocyte cell proportions over 10% and an LDH level less than twice the upper limit of normal (ULN) for the testing laboratory were identified. Anonymized clinical data were then analyzed to determine risk factors for thrombosis. Comparisons between those with and without thrombosis were assessed.
A total of 429 patients were analyzed and 25 patients who fit the criteria were identified. Median age of the patient cohort was 60 years (range 23 to 80 years). Eleven patients fit the criteria for group 1 (PNH white cells >30%, PNH red cells <10%, LDH <2×ULN), of whom six (54%) had thrombosis. Eleven patients fit the criteria for group 2, (PNH white cells >30%, PNH red cells >10% with higher proportion of type II red cells than type III red cells, LDH <2×ULN) of whom 2 (18.1%) had thrombosis. Three patients fit the criteria for group 3, (PNH white cells 10%-30%, PNH red cells <10%, LDH <2×ULN) with no thrombosis. Median age at thrombosis was 49 years (range 21-67 years).
Patients at higher risk of presenting with thrombosis were those with high PNH white cell proportions and low PNH red cells (group I). Patients with a greater proportion of type II red cells (partial deficiency of GPI linked proteins) compared to type III red cells (complete deficiency of GPI linked proteins) and LDH <2× ULN were also at risk of thrombosis. This is an under-recognized risk for patients with PNH cells.
The authors concluded that that while hemolysis may be associated with a thrombotic event, white cell and platelet factors appear to have a more pivotal role than previously thought in the mechanisms of thrombosis in PNH. The study was published in the March 2019 issue of the journal Haematologia.
Related Links:
St James University Hospital
PNH stem cells arise due to somatic mutations in the phosphatidylinositol glycan A (PIGA) gene in bone marrow stem cells, resulting in loss of the glycosylphosphatidylinositol anchor protein (GPI anchor). Loss of this GPI anchor results in absence of CD55 and CD59, complement regulatory proteins on hematopoietic cells, rendering red blood cells susceptible to complement attack and intravascular hemolysis.
Hematologists at St James University Hospital (Leeds, UK) and their colleagues retrospectively interrogated the Leeds (UK) PNH database. Patients with PNH granulocyte or monocyte cell proportions over 10% and an LDH level less than twice the upper limit of normal (ULN) for the testing laboratory were identified. Anonymized clinical data were then analyzed to determine risk factors for thrombosis. Comparisons between those with and without thrombosis were assessed.
A total of 429 patients were analyzed and 25 patients who fit the criteria were identified. Median age of the patient cohort was 60 years (range 23 to 80 years). Eleven patients fit the criteria for group 1 (PNH white cells >30%, PNH red cells <10%, LDH <2×ULN), of whom six (54%) had thrombosis. Eleven patients fit the criteria for group 2, (PNH white cells >30%, PNH red cells >10% with higher proportion of type II red cells than type III red cells, LDH <2×ULN) of whom 2 (18.1%) had thrombosis. Three patients fit the criteria for group 3, (PNH white cells 10%-30%, PNH red cells <10%, LDH <2×ULN) with no thrombosis. Median age at thrombosis was 49 years (range 21-67 years).
Patients at higher risk of presenting with thrombosis were those with high PNH white cell proportions and low PNH red cells (group I). Patients with a greater proportion of type II red cells (partial deficiency of GPI linked proteins) compared to type III red cells (complete deficiency of GPI linked proteins) and LDH <2× ULN were also at risk of thrombosis. This is an under-recognized risk for patients with PNH cells.
The authors concluded that that while hemolysis may be associated with a thrombotic event, white cell and platelet factors appear to have a more pivotal role than previously thought in the mechanisms of thrombosis in PNH. The study was published in the March 2019 issue of the journal Haematologia.
Related Links:
St James University Hospital
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more